Turner et al reported that in 363 participants with essential hypertension, a lower plasma renin activity (PRA) predicted a better blood pressure-lowering response to hydrochlorothiazide (12.5–25 mg/day) compared to atenolol (50–100 mg/day), both as monotherapy and as an add-on [40]. The gene discussed is REN; the disease is hypertensive disorder.